Clinical trials with trastuzumab deruxtecan (T-Dxd, DS-8201) have shown impressive results in metastatic HER2-low breast cancer, defined by 1 + and 2 + immunohistochemistry (IHC) scores without HER2 gene amplification [5]. Here, ERBB2 is linked to breast carcinoma.